Thyroid hormone (TH) is essential for vertebrate development and the homeostasis of most adult tissues, including bone. TH stimulates target gene expression through the nuclear thyroid receptors TRa and TRb; however, TH also has rapid, transcription-independent (nongenomic) effects. We found a previously uncharacterized plasma membrane-bound receptor that was necessary and sufficient for nongenomic TH signaling in several cell types. We determined that this receptor is generated by translation initiation from an internal methionine of TRa, which produces a transcriptionally incompetent protein that is palmitoylated and associates with caveolin-containing plasma membrane domains. TH signaling through this receptor stimulated a pro-proliferative and pro-survival program by increasing the intracellular concentrations of calcium, nitric oxide (NO), and cyclic guanosine monophosphate (cGMP), which led to the sequential activation of protein kinase G II (PKGII), the tyrosine kinase Src, and extracellular signal-regulated kinase (ERK) and Akt signaling. Hypothyroid mice exhibited a cGMP-deficient state with impaired bone formation and increased apoptosis of osteocytes, which was rescued by a direct stimulator of guanylate cyclase. Our results link nongenomic TH signaling to a previously uncharacterized membrane-bound receptor, and identify NO synthase, guanylate cyclase, and PKGII as TH effectors that activate kinase cascades to regulate cell survival and proliferation.
INTRODUCTION
Thyroid hormones (THs), including thyroxine (T4) and its more active derivative triiodothyronine (T3), regulate gene expression by binding to nuclear thyroid receptors (TRs). The latter bind to TH-responsive elements (TREs) in target gene promoters as homodimers or as heterodimers with the retinoic acid receptor RXR (1, 2) . Free TRs repress basal transcription, but the binding of TH to TRs induces a conformational change, releasing co-repressors, recruiting co-activators, and activating transcription of target genes within hours to days (1) . Two TR genes (THRA and THRB) generate multiple TRa-and TRb-encoding mRNAs; some encode proteins that do not bind to TH, but are transcriptional antagonists (1, 3) .
TH has transcription-independent, nongenomic effects that occur within seconds to minutes through poorly defined mechanisms (1) . In myocytes and neurons, TH increases the concentration of free intracellular calcium (Ca 2+ ), which contributes to positive cardiac inotropy and chronotropy, whereas in vascular cells, TH activates endothelial nitric oxide synthase 3 (NOS3), which leads to vasodilation (4) (5) (6) . In many cell types, TH activates extracellular signal-regulated kinases 1 and 2 (ERK1/2), thereby increasing cell proliferation (1, (7) (8) (9) . ERK activation is thought to occur through the low-affinity binding of T3 or T4 to the integrin a v b 3 (1, 7, 10) ; however, TH binds to cell membranes with high affinity, and subnanomolar concentrations of T3 stimulate ion channels in the plasma membrane (1, 2, 4, 11) . These data suggest that a high-affinity TH receptor exists in the plasma membrane; however, it has not yet been identified.
Among its many physiological functions, TH regulates bone growth and remodeling, stimulating osteoclasts to resorb bone and osteoblasts to produce new bone. Osteoclast stimulation occurs largely through the production of the osteoclast-stimulating cytokine RANKL (receptor activator of nuclear factor kB ligand) by osteoblasts (12) . Excess TH leads to high-bone turnover osteoporosis because osteoclasts outpace osteoblasts, whereas a decreased TH concentration leads to brittle bones from decreased bone turnover because of reduced osteoblast and osteoclast activities (12) . Both states lead to increased bone fractures, and even subclinical changes in thyroid status affect bone metabolism and may increase fracture risk in older people (12) . We previously showed that NO stimulates ERK and Akt in osteoblasts and osteocytes (13) (14) (15) . Here, we used osteoblasts as a model system to study nongenomic TH signaling. We found that TH activated the NO-cyclic guanosine monophosphate (cGMP)-protein kinase G (PKG) signaling cascade through a previously uncharacterized, plasma membrane-associated TRa isoform, thereby stimulating Src, ERK, and Akt. This signaling mechanism occurs in multiple cell types, and is physiologically relevant, enhancing osteoblast proliferation and survival in vitro and bone formation in vivo.
RESULTS

Nongenomic TH signaling requires a TRa isoform
In human primary osteoblasts (hPOBs) and mouse osteoblast-like MC3T3 cells, 1 nM T3 stimulated the phosphorylation (and activation) of Src, ERK1/2, and Akt within 2 to 5 min, with the extent of phosphorylation returning to basal amounts at 20 to 30 min after treatment (Fig. 1A and fig.  S1 , A and B). Concentrations of T3 as low as 10 −11 M were effective, whereas 10 −8 to 10 −7 M T4 was required for kinase activation; the inactive T3 isomer reverse T3 (rT3) was without effect at 10 −7 M (Fig. 1B and fig. S1C ). These results suggest the involvement of a classic TR because T3 and T4 bind to TRs at subnanomolar (K D < 10 −9 M) and high-nanomolar (~10 −7 M) concentrations, respectively (16) . To assess whether TRa or TRb mediated the effects of TH, we isolated POBs from mice with floxed THRA or THRB alleles. That the THRA f/f and THRB f/f cells were osteoblasts was demonstrated by their differentiation potential (fig. S1A), and recombination by the site-specific recombinase Cre (cyclization recombination) reduced the abundances of TRa and TRb mRNAs by~70% ( fig. S1D ). Depletion of TRa, but not TRb, prevented the T3-dependent phosphorylation of ERK and Akt, whereas reconstituting TRa-depleted cells with TRa1 restored their responsiveness to T3 (Fig. 1, C and D,  and fig. S1E ). We found similar results in experiments with MC3T3 cells that were treated with TRa-and TRb-specific small interfering RNAs (siRNAs); however, TRb1 could not substitute for TRa1 in TRa-depleted cells ( Fig. 1E and fig. S1 , F and G).
Previously uncharacterized TRa isoforms mediate nongenomic TH signaling
Multiple TRa forms are expressed from the THRA gene through differential splicing (including TRa1 and TRa2) and transcription from an intronic promoter (TRDa1 and TRDa2), but only the full-length TRa1 mRNA encodes a ligand-binding receptor ( Fig. 2A) (3) . We found four TRa1 isoforms of~30, 33, 43, and 48 kD in size in MC3T3 cell extracts, which were reduced markedly in abundance in cells transfected with TRaspecific siRNA, but were restored in cells infected with adenovirus encoding siRNAresistant rat TRa1 (Fig. 2B and fig. S2A ). The anti-TRa1 antibody does not recognize TRb ( fig. S2B ). These four isoforms were also observed in cells transfected with plasmid encoding FLAG-tagged TRa1 and were detectable over a 10-fold range of abundance ( Fig. 2C and fig. S2C ). At the lowest amount of transfected DNA, the amount of protein was similar to that of endogenous TRa1 ( fig. S2C ), with the epitope-tagged proteins migrating with a higher apparent molecular mass ( fig. S2D ). In contrast, cells transfected with plasmid encoding FLAGtagged TRb1 produced only a single protein ( fig. S2B ).
The 48-kD TRa1 isoform represents the full-length receptor, and the 43-kD isoform is likely mitochondrial TRa1, which initiates translation from Met 39 and functions as a mitochondrial transcription factor (17) . We hypothesized that the other two isoforms originated from additional internal translation initiation codons. Because translation initiation from an AUG codon depends primarily on infected with control (LacZ-expressing) or Creexpressing viruses. Forty-eight hours later, the cells were treated with vehicle or 1 nM T3 for 5 or 10 min. Phosphorylation of ERK and Akt was assessed as described for (A) and (B). The bar graphs show data for the 10-min time points, with vehicle-treated, control virus-infected cells assigned a value of 1. Data are means ± SEM from three independent experiments. **P < 0.01, ***P < 0.001 compared to vehicle-treated cells; ### P < 0.001 compared to T3-treated, control virus-infected cells. (E) MC3T3 cells were transfected with siRNAs specific for green fluorescent protein (GFP) or TRa and then were infected with viruses encoding LacZ, FLAG-tagged TRa1, or FLAG-tagged TRb1. Cells were treated with vehicle or T3 for 10 min. Knockdown efficiency is shown in Fig. 2B and fig. S1G . Virus expression was assessed by Western blotting of cell lysates with an anti-FLAG antibody. Bar graph shows the means ± SEM of the relative amounts of pERK and pAkt in the indicated samples. Data are from three independent experiments. ## P < 0.01, ### P < 0.001 compared to cells transfected with GFP-specific siRNA; **P < 0.01 for the indicated comparison. fig. S2D ; data are representative of five experiments). (E and F) MC3T3 cells were transfected with siRNAs targeting GFP (first two lanes) or TRa (all other lanes) and then were infected with viruses encoding the TRa1 constructs described in (D). D119 PH refers to a TH binding-deficient mutant (P398H). Cells were treated with vehicle or 1 nM T3 for 10 min and then were analyzed by Western blotting to determine ERK and Akt activation as described in Fig. 1 , A and B. Western blots were analyzed with anti-FLAG antibody to determine the extent of viral infection. ns, nonspecific. Graphs show the means ± SEM of the fold increase in the abundances of pERK and pAkt from three independent experiments. Cells that were transfected with GFP-specific siRNA, infected with control virus, and treated with vehicle were assigned a value of 1. **P < 0.01, ***P < 0.001 compared to cells transfected with TRa-specific siRNA and infected with control virus; ## P < 0.05 compared to cells transfected with TRa-specific siRNA and infected with virus encoding WT TRa. (G) MC3T3 cells were cotransfected with a TREcontaining luciferase reporter plasmid and with empty vehicle or with plasmids encoding the indicated TRa1 constructs described in (D). Cells were then treated with vehicle or T3 for 24 hours. Data in the bar graph are means ± SEM of the relative luciferase activities in the indicated samples and are from five independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 for the indicated comparisons; # P < 0.05 compared to cells transfected with empty plasmid and treated with T3. (Fig. 2D) . Thus, we found that the 30-and 33-kD TRa1 isoforms were produced from internal translational start codons.
To determine whether the 30-kD, 33-kD, or both TRa1 isoforms mediated nongenomic TH signaling, we reconstituted TRa-depleted MC3T3 cells with several TRa1 constructs. The D119 and D149 TRa1 constructs restored T3-dependent ERK and Akt activation, but the D119 PH mutant construct did not (Fig. 2E) (Fig. 2F) . The Mut x3 protein had normal transcriptional activity, whereas the D119 and D149 mutants were not transcriptionally active and suppressed T3-induced transcription by endogenous TH receptor or by overexpressed wild-type TRa1 in transfected cells (Fig. 2G and  fig. S2E ). This dominant-negative effect is likely a result of heterodimerization between the wild-type and truncated receptors, with the latter lacking DNA-binding and transactivation domains. Nongenomic TH signaling by the TRa1-D149 mutant also occurred in NIH-3T3 fibroblasts and MDA-MB231 breast cancer cells. T3-dependent ERK and Akt activation was blocked by siRNA-mediated loss of TRa and was restored by reconstituting the cells with TRa1-D149 ( fig. S2, F to I) . Thus, the 30-kD, 33-kD, or both TRa1 isoforms are necessary and sufficient to mediate nongenomic TH signaling.
The 30-kD TRa isoform (p30 TRa1) is palmitoylated and colocalizes with caveolin-1 and NOS3 in plasma membranes
The 30-kD, but not the 33-kD, TRa1 isoform was present in osteoblast membrane fractions. It comigrated with the peptide initiated from Met 150 and was depleted in cells transfected with TRa-specific siRNA (Fig. 3A  and fig. S3A ). This protein, which we refer to as p30 TRa1, was retained on T3-Sepharose, even in the absence of cofactors, but was not retained on control resin (Fig. 3B and fig. S3 , B to D). It was also detected by a second antibody directed against a different C-terminal TRa1 epitope ( fig. S3B) . Similar results were obtained in experiments with NIH-3T3 fibroblasts ( Fig. 3C and fig. S3E ).
Through gradient centrifugation, we isolated light buoyancy membrane lipid rafts-cholesterol-rich plasma membrane microdomains that contain caveolin-1 and function as unique signal transduction platforms (20) . p30 TRa1 tracked with caveolin-1 in lipid rafts from murine POBs, whereas in MC3T3 cells expressing Myc-tagged p30 TRa1, p30 TRa1 tracked with caveolin-1, NOS3, PKGII, and Src (Fig. 3, D and E) . The association of proteins with plasma membranes can be mediated by posttranslational lipid modifications, and sequence analysis of p30 TRa1 predicted that Cys 254 , Cys 255 , or both were potential palmitoylation sites (CSS-Palm 3.0). We found that [ 14 C]palmitic acid was incorporated into p30 TRa1, and that the palmitoylation inhibitor 2-bromo-palmitate and the cholesterol-depleting agent methyl-b-cyclodextrin blocked T3-dependent ERK and Akt activation ( Fig. 3F and fig. S3, F , or both are required for the membrane targeting of p30 TRa1 and its signaling. In contrast, the myristoylation inhibitor 2-hydroxymyristic acid had no effect on the membrane localization of p30 TRa1, although it blocked the membrane association of PKGII ( fig. S3H ).
To assess whether p30 TRa1 colocalized with caveolin-1, we used two approaches in MC3T3 cells expressing epitope-tagged p30 TRa1. First, we used a proximity ligation assay (PLA), by which the juxtaposition of two antibodies covalently linked to oligodeoxynucleotides enables the formation of circular DNA strands and replication by a rolling-circle amplification reaction. With this assay, we observed punctate signals of amplified DNA (red) on the plasma membrane, indicating that p30 TRa1 and caveolin-1 were within~40 nm of each other (Fig. 3I) (21) . Second, through double immunofluorescence staining, we found that p30 TRa1 colocalized with caveolin-1 on the plasma membrane (Fig. 3, J and K) . Thus, p30 TRa1 associates with caveolin-1-containing membrane microdomains, which contain NOS3, PKGII, Src, and other signaling molecules (20, 22) .
TH activates ERK and Akt through Ca
2+
, NOS3, membrane-bound PKGII, Src, and the integrin b 3 subunit TH activates NOS1 and NOS3 isoforms in several cell types (5, 6) , and the NO-dependent activation of soluble guanylate cyclase (sGC) and PKG leads to the activation of Src, ERK, and Akt in osteoblasts (Fig. 4A) (15) . Thus, we hypothesized that TH signals to ERK and Akt through the NO-cGMP-PKG pathway. We found that T3 stimulated osteoblasts to produce NO, and that this required TRa, but not TRb (Fig. 4B) . T3 increased NO production in THRA f/f POBs exposed to control virus but not Cre virus, whereas in THRB f/f POBs, T3 increased NO production in the presence or absence of Cre (Fig. 4B and fig. S1D ). In TRa-depleted osteoblasts, reconstitution of cells with p30 TRa1 restored T3-dependent NO production, whereas Mut x3 TRa had no effect (Fig. 4C and fig.  S4A ). The T3-dependent increase in NO was blocked by the nonselective NOS inhibitor N-nitro-L-arginine methyl ester (L-NAME) and by the extracellular Ca 2+ chelator EGTA ( Fig. 4D and fig. S4B ). EGTA blocked the rapid T3-dependent increase in intracellular Ca 2+ (Fig. 4E ). These data suggest that T3 activates Ca 2+ -dependent NOS1 or NOS3. We found that NOS3 was the target because T3 failed to increase NO production in NOS3-deficient POBs, and NOS3 was required for the T3-dependent activation of PKG, ERK, and Akt (Fig. 4 , F and H, and fig. S4C ). NOS3 can also be activated by its phosphorylation by Akt on Ser
1177
, and we found that the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 blocked T3-dependent Akt activation and NOS3 phosphorylation on Ser
, as well as reduced NO production (Fig. 4 , D and G, and fig. S4B ). We conclude that T3 activates NOS3 both directly by increasing the concentration of intracellular Ca 2+ and indirectly through the Akt-dependent phosphorylation of Ser 1177 (23) . To assess whether sGC or PKG was required for nongenomic TH signaling, we used pharmacological activators or inhibitors of both enzymes (Fig. 4A) , and found that activators stimulated, whereas inhibitors blocked, the T3-dependent activation of Src, ERK, and Akt (Fig. 4, I and J, and fig.  S4D ). To determine which PKG isoform was involved, we used an siRNAbased approach. Depleting PKGI had no effect, but depleting PKGII completely blocked the T3-dependent activation of Src, ERK, and Akt (Fig. 4 , K and L). Signaling was restored in cells reconstituted with wildtype PKGII, but not with a myristoylation-deficient mutant PKGII (G2A), which does not bind to the plasma membrane ( Fig. 4M) (14) . Moreover, 2-hydroxymyristic acid blocked the T3-dependent activation of ERK and Akt ( fig. S4E ). We previously demonstrated that PKGII activates Src bound to the cytoplasmic tail of the integrin b 3 subunit through stimulation of the Src homology domain 2-containing phosphatases SHP-1 and SHP-2 (14) . Here, we found that the T3-induced activation of ERK and Akt required Src, SHP-2, and the integrin b 3 subunit ( fig. S4, F and G) . The latter finding may explain the role of the integrin b 3 subunit in T3-dependent ERK activation (7, 10) . Consistent with published data (10), we found that integrin a v b 3 bound to T3-Sepharose, but the presence or absence of a v b 3 did not affect the binding of T3 to p30 TRa1 ( fig. S4, H and I) . Depletion of the b 3 integrin subunit reduced T3-stimulated NO production by~50%, likely because the stimulation of NOS3 by T3 requires b 3 -dependent Akt activation in addition to Ca 2+ influx ( fig. S4 , C, F, and J). These data suggest a previously uncharacterized signaling pathway from p30 TRa1 to ERK and Akt through Ca 2+ , NOS3, PKGII, and Src.
Nongenomic TH signaling through the p30 TRa1-NO-cGMP pathway stimulates cell proliferation and survival
Because ERK and Akt are linked to cellular proliferation and survival, we investigated whether TH regulated the proliferation and survival of osteoblasts through the p30 TRa1-NOS3 pathway. T3 increased the number of POBs and MC3T3 cells in S phase by two-to threefold, with TRa, but not TRb, being required for the increased DNA synthesis (Fig. 5, A and B, and fig. S5A ). In TRa-depleted osteoblasts, reconstitution with full-length, wild-type TRa1 completely restored proliferation, whereas reconstitution with p30 TRa1 or the full-length Mut x3 TRa1 only partly restored proliferation ( Fig. 5B and fig. S5A ). These data suggest that membraneinitiated T3 signaling through p30 TRa1 cooperates with nuclear T3 signaling to promote osteoblast growth. Because the Cre-mediated reduction of TRa abundance did not affect basal osteoblast proliferation in hormone-free medium, the amount of apo-TRa did not appear to influence osteoblast proliferation under the experimental conditions. T3-dependent proliferation required T3 protected POBs and osteocyte-like MLO-Y4 cells from death induced by serum starvation or treatment with the topoisomerase inhibitor etoposide, respectively; however, protection was lost by depleting TRa in THRA f/f POBs, but was completely restored by reconstituting the cells with p30 TRa1 (Fig. 5E and fig. S5C ). T3-mediated protection from serum starvation required NOS3 because T3 had no effect in Cre-treated NOS3 f/f POBs (Fig. 5, F and G) . The NO-independent sGC stimulator cinaciguat bypassed the requirement for T3 and NO and protected NOS3 f/f POBs in the absence and presence of Cre (Fig. 5F ). PKG, MEK, and PI3K inhibitors prevented the antiapoptotic effects of T3 in hPOBs and MLO-Y4 cells (Fig. 5H and fig. S5C ). Thus, the pro-proliferative and antiapoptotic effects of T3 in osteoblasts require signaling by p30 TRa1 through NO-cGMP, PKG, MEK-ERK, and PI3K-Akt.
In murine POBs and MC3T3 cells, T3 increased the expression of proliferation-associated fos family genes (c-Fos and Fosl1), but this effect was blocked by L-NAME, ODQ, Rp-CPT-PET-cGMPS, or U0126 (Fig. 5I  and fig. S5D ), consistent with the expression of these genes being regulated by NO-cGMP-PKG and ERK-dependent pathways (13) . L-NAME also prevented the T3-dependent increase in the abundance of osteocalcin (Bglap2) and osteopontin (Ssp1) mRNAs in differentiating mPOBs, but it did not reduce the T3-dependent increase in RANKL (Tnfsf11) mRNA abundance, consistent with RANKL being a direct genomic TR target (Fig. 5I) (24) . Expression of the RANKL antagonist osteoprotegerin (Tnfrsf11b) was unaffected by T3 or L-NAME. Thus, the T3-dependent regulation of genes associated with the proliferation and differentiation of osteoblasts required NO signaling, whereas the T3-dependent production of RANKL was independent of NO.
Hypothyroid mice are cGMP-deficient, and increasing cGMP abundance improves bone formation and prevents apoptosis of osteocytes Hypothyroidism is characterized by reduced bone turnover because of decreased osteoblast and osteoclast activities (12) . To determine the physiological relevance of cGMP-dependent TH actions in vivo, we examined the skeletal effects of the NO-independent sGC stimulator cinaciguat in hypothyroid mice. Cinaciguat is a prototype of a new class of cGMPenhancing agents that are in clinical development (25) . Mice were fed an iodine-deficient diet containing the deiodinase inhibitor propylthiouracil (PTU) for 4 weeks, and they received daily injections of vehicle or cinaciguat, the latter at a dose that transiently reduces systolic blood pressure (25) . The iodine-deficient, PTU-containing diet induced severe hypothyroidism as evidenced by the reduced serum T3 and T4 concentrations and the slowed heart rates of the affected mice (Fig. 6A ). The hypothyroid mice had markedly reduced serum cGMP concentrations (Fig. 6B) , consistent with decreased NOS activity in hypothyroid animals (6, 26) . Similar amounts of NOS3 mRNA were present in the bones of hypothyroid and control mice ( fig. S6A ). Cinaciguat substantially increased the serum cGMP concentrations of treated mice, indicating effective sGC stimulation, but it had no effect on the serum concentrations of T3 or T4 or on heart rate (Fig. 6,  A and B) .
At 7 and 4 days before euthanasia, mice were injected with calcein to identify newly formed bone on endosteal and trabecular surfaces (Fig. 6 , C and D). Control animals had double labeling over 9% of their femoral endosteal surface, whereas hypothyroid mice had only single labeling, indicating a low rate of mineral apposition during the 3 days between calcein injections (Fig. 6, D and E) . Moreover, hypothyroid mice had statistically significantly decreased mineral apposition and bone formation rates (Fig.  6, F and G, and fig. S6 , B and C). Cinaciguat restored double calcein labeling and largely restored mineral apposition and bone formation rates in hypothyroid mice, indicating that increased cGMP production could at least partly substitute for TH in supporting osteoblast functions (Fig. 6, D  to G, and fig. S6 , B and C). The hypothyroid mice had decreased serum concentrations of the osteoblast marker procollagen 1 N-terminal peptide (P1NP) and the osteoclast marker C-terminal telopeptide (CTX) (Fig. 6, H  and I ). Cinaciguat partly restored P1NP, but did not affect CTX (Fig. 6, H  and I ). The number of trabecular osteoblasts and osteoclasts was decreased in the hypothyroid mice compared to those in control animals, and cinaciguat partly restored osteoblast numbers, but did not statistically significantly affect osteoclasts (Fig. 6, J and K, and fig. S6, D and E) . Endocortical osteoid surface and width were reduced in the hypothyroid mice, with a trend toward increased values in cinaciguat-treated animals that did not reach statistical significance ( fig. S6, F and G) .
Consistent with the NO-and cGMP-dependent antiapoptotic effects of T3 in osteoblasts and osteocytes in vitro (Fig. 5, E to H, and fig. S5C ), osteocytes in the cortical and trabecular bones of hypothyroid mice showed increased apoptosis, with cinaciguat returning the number of apoptotic cells to normal (Fig. 6, L and M, and fig. S6, H and I) . The amounts of p30-TRa1 protein were similar in membrane extracts from bones of hypothyroid and control mice ( fig. S6J ). The mRNA abundances of the osteoblast differentiation marker osteocalcin (Bglap2) and osteoblast-and osteocytederived RANKL (Tnfsf11) were reduced in the tibiae of hypothyroid mice compared to those in the tibiae of normal mice, with cinaciguat fully restoring gene expression (Fig. 6N) . The abundance of the RANKL antagonist osteoprotegerin (Tnfrsf11b) was unchanged under all conditions (Fig. 6N) . The T3-dependent production of RANKL in isolated mPOBs was independent of NO ( Fig. 5I) , but the effect of cinaciguat on RANKL mRNA abundance in hypothyroid mice may be a result of its effects on osteoblast and osteocyte survival. We conclude that decreased bone formation-with reduced osteoblast numbers and activity-and increased osteocyte apoptosis in hypothyroid mice are a result, at least in part, of a relatively NO-and cGMP-deficient state, which may be caused by decreased nongenomic TH signaling. Fig. 2 . (E to G) Cells were then subjected to serum deprivation for 18 hours in the presence or absence of (E to G) 1 nM T3 or (F) 1 nM T3 or 100 nM cinaciguat (Cin). Cell death was assessed by (E and F) trypan blue uptake or (G) Western blotting analysis for cleaved caspase-3. Bar graphs show the means ± SEM of the percentages of dead cells from three or four independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 compared to cells infected with LacZ-encoding virus and treated with T3; ## P < 0.01 for cells infected with LacZ-encoding virus compared to cells infected with TRa-encoding virus and treated with T3 (E) and for cinaciguattreated compared to vehicle-treated cells in (F). (H) hPOBs were treated as described in (D), starved of serum, and analyzed as described in (E). Data are means ± SEM of the percentages of dead cells from four independent experiments. **P < 0.001 compared to vehicle-treated cells; # P < 0.05 compared to cells treated with T3 alone. (I) mPOBs were treated with vehicle or 1 nM T3 in the presence or absence of 4 mM L-NAME (L-NA) for 1 hour (left, undifferentiated cells) or 24 hours (right, differentiated cells). The relative abundances of the mRNAs for c-Fos, Fosl1, osteocalcin (Bglap2), osteopontin (Spp1), RANKL (Tnfsf11), and osteoprotegerin (Tnfrsf11b) were quantified by RT-PCR analysis and were normalized to that of HGPRT mRNA. The mean abundance of each transcript measured in vehicle-treated cells was assigned a value of 1. Data are means ± SEM of the fold increase in the indicated mRNA from three to six independent experiments. ***P < 0.001 for T3-treated cells compared to vehicle-treated cells; # P < 0.05, ### P < 0.001 compared to cells treated with T3 alone. Fig. 6 . Hypothyroid mice are cGMP-deficient, but increasing their cGMP concentration improves bone formation and prevents osteocyte apoptosis. Twelve-week-old male C57BL6 mice were fed a control diet or an iodine-deficient diet containing 0.15% PTU for 4 weeks. During this time, mice received daily injections of either vehicle or cinaciguat (10 mg/kg). Calcein was injected 7 and 4 days before euthanasia. (A) Heart rate was measured 2 weeks after starting the diet, whereas serum T3 and T4 concentrations were measured at the time of euthanasia. Data are means ± SEM from seven mice for each condition. *P < 0.05, **P < 0.01, ***P < 0.001 compared to mice fed a control diet. (B) Serum cGMP concentrations were measured 2 hours after the last injection with cinaciguat. Data are means ± SEM from seven mice for each condition. *P < 0.05, ***P < 0.001 for the indicated comparisons. (C) Endosteal cortical bone surface and the area analyzed for trabecular bone are indicated by a black line on a trichrome-stained distal femur. (D) Femoral endosteal calcein labeling was assessed by fluorescence microscopy. Scale bar, 10 µm. (E) Single-and double-labeled surfaces were measured by fluorescence microscopy and were expressed as a percentage of the total endosteal bone surface between 0.25 and 5 mm from the growth plate. ND, not detected. (F and G) Mineral apposition rate (MAR) (F) and bone formation rate (BFR) (G) were calculated from the interlabel distances. Data in (E) to (G) are means ± SEM from six mice for each condition. *P < 0.05, **P < 0.01, ***P < 0.001 for the indicated comparisons. A minimal MAR value of 0.3 mm/day was assigned to the PTU group, which showed only single-labeled surfaces. (H and I) Serum concentrations of procollagen-1 N-terminal peptide (P1NP) and C-terminal telopeptide (CTX) for the indicated mice were measured by enzyme-linked immunosorbent assay. (J and K) The numbers of (J) osteoblasts (N.Ob) and (K) osteoclasts (N.Oc) per millimeter of trabecular bone perimeter (B.Pm) were counted for the indicated mice. Data in (H) to (K) are means ± SEM from six mice for each condition. *P < 0.05, **P < 0.01, ***P < 0.001 for the indicated comparisons. (L) Apoptotic osteocytes were identified in the cortical bone by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining (black nuclei). Data are representative of four mice per group. (M) Bar graph shows the means ± SEM of the percentages of TUNEL + osteocytes from four mice for each group. (N) RNA was extracted from femurs from the indicated mice, and the relative abundances of osteocalcin (Bglap1), RANKL (Tnfsf11), and osteoprotegerin (Tnfrsf11b) mRNAs were quantified by RT-PCR analysis and normalized to that of glyceraldehyde-3-phosphate dehydrogenase (gapdh) mRNA. Mean values of the control group were assigned a value of 1. Data are means ± SEM from five or six mice for each condition. *P < 0.05, **P < 0.01 for the indicated comparisons.
DISCUSSION
Nongenomic TH signaling via a plasma membraneassociated TRa isoform TH rapidly stimulates the generation of second messengers such as Ca 2+ , NO, inositol trisphosphate, and cAMP in various cells. A membraneassociated member of the TH receptor family has been proposed, but evidence for such a receptor has been lacking (1, 2) . Instead, the integrin a v b 3 was suggested to serve this function (10) . Here, we showed that T3 and T4 rapidly activated ERK and Akt at concentrations compatible with binding to a high-affinity TR, and that ERK and Akt activation required TRa, but not TRb. We discovered a previously uncharacterized 30-kD TRa1 receptor that was necessary and sufficient to mediate T3-induced ERK and Akt activation in multiple cell types. This receptor is palmitoylated and colocalizes with caveolin-1 in cholesterol-enriched microdomains in the plasma membrane. Thus, it is positioned to signal through NOS3, PKGII, and Src, which reside in the same membrane microdomains (20, 22) .
We showed that p30 TRa1 was translated from Met 150 of TRa1, whereas the mitochondrial 43-kD TRa1 isoform was translated from Met 39 (17) . Alternative translation start sites within a single transcript are conserved in eukaryotic genomes and contribute to proteome diversity, but translation initiation from AUGs more than 50 codons downstream of the first start codon is uncommon (18) . The use of alternative translation start sites is thought to occur by leaky ribosomal mRNA scanning and is typically associated with an unfavorable Kozak consensus sequence around the upstream initiation codon(s), as is the case with TRa. In vitro translation of chicken TRa mRNA in reticulocyte lysates generates peptides of 48, 40, 30, and 27 kD, suggesting that ribosomal scanning and reinitiation occur in vitro as well as in vivo (27) 150 was detected in membranes. Thus, how translational initiation from downstream AUG codons is regulated requires further study. The specificity of the anti-TRa1 antibody that we used was documented in experiments involving siRNA-based depletion and reconstitution of TRa1, but available TRa1-specific antibodies are weak and p30 is not abundant, which may explain why the membrane-associated TRa has not been observed previously. The physiological relevance of the p30 TRa1 isoform is implied by reconstitution experiments in TRa-depleted osteoblasts because reconstitution with p30 TRa1 partly restored T3-dependent proliferation and fully restored T3-induced NO production, ERK and Akt activation, and cell survival.
Molecular mechanisms of nongenomic TH signaling involving the integrin b 3 subunit
We found that T3 rapidly increased the intracellular Ca 2+ concentration in osteoblasts, leading to increased NO production through NOS3 activation. In addition, we found that T3 activated NOS3 by Akt-mediated phosphorylation of Ser 1177 , similar to events in endothelial cells (6) . The siRNA-mediated depletion of the integrin b 3 subunit blocked T3-induced Akt activation completely, whereas it inhibited NO production by~50%. We propose that T3 rapidly activates NOS3 by intracellular Ca 2+ influx and that the resultant stimulation of the NO-cGMP-PKG pathway activates Akt to maintain increased NOS3 activity (Fig. 7) .
The T3-dependent activation of ERK and Akt occurred through the NOand cGMP-dependent activation of PKGII and required SHP-2, Src, and the integrin b 3 subunit. We showed previously that PKGII phosphorylates and activates the tyrosine phosphatase complex consisting of SHP-1 and SHP-2, which dephosphorylates and activates Src bound to the cytoplasmic tail of b 3 integrin subunits (14) . In cooperation with focal adhesion kinase, Src then activates ERK and Akt (15) . Activation of Src, ERK, and Akt by TH likely occurs through a similar pathway (Fig. 7) , which explains why antibodies that block b 3 integrin subunits and siRNA-mediated depletion of b 3 block TH-induced ERK and Akt activation (1, 7, 10) . Thus, nongenomic TH signaling through p30 TRa converges on a common final pathway that mediates anabolic effects in bone in response to multiple upstream signals, including mechanical stimuli, growth factors, and hormones.
Other workers have observed that T3-induced activation of Akt occurs through the direct interaction of p85 PI3K with either full-length TRa1 or TRb, depending on the cell type (6, (28) (29) (30) (31) . A mutant TRb pv/pv receptor promotes the constitutive activation of PI3K and Akt in thyroid cancer cells, and TRb colocalizes with p85 in cytosolic and nuclear compartments. Heterologous expression of TRb in Chinese hamster ovary cells reconstituted the PI3K-dependent regulation of a potassium channel at the plasma membrane (30, 32) . We do not exclude the possibility of parallel pathways that mediate T3-induced Akt activation; however, in osteoblasts, TRb could not substitute for TRa, and full-length TRa with mutations in Met Comparison between thyroid and steroid hormone nongenomic signaling
TRa and TRb belong to the steroid receptor superfamily and, similar to sex hormone receptors, are phylogenetically young, being found only in vertebrates. Estrogens, androgens, and progestins exert rapid, nongenomic effects through membrane-bound receptors, with membrane-bound isoforms of estrogen receptor a (ERa) generated by differential mRNA splicing (33) . The plasma membrane association of ERa requires its palmitoylation at a cysteine located within a nine-amino acid motif that is conserved in most steroid receptors, except for TRa (34) . We found that p30 TRa1 is palmitoylated, but that the cysteine(s) necessary for membrane association and nongenomic TH signaling is located N-terminal to the ligand-binding cavity (35) . Palmitoylation, protein-protein interaction sites, or both may be obscured by interdomain interactions in full-length TRa. This would explain why expression of the full-length Mut x3 TRa1 protein did not reconstitute nongenomic TH signaling in TRa-deficient cells. We found that p30 TRa1 was necessary, but not sufficient, for T3-induced osteoblast proliferation. The full-length Mut x3 TRa1 protein supported some proliferative effects in TRa-depleted osteoblasts, suggesting cooperation between membrane-initiated and nuclear T3 signaling. Similarly, nongenomic estrogen signaling through membrane-associated ER is necessary, but not sufficient, for the pro-proliferative effects of the hormone (34) . In contrast, p30 TRa1 fully reconstituted the antiapoptotic effects of T3 in TRa-depleted osteoblasts, and nongenomic estrogen signaling fully protects osteoblasts from apoptosis in the absence of nuclear signaling (36) . Membrane-bound p30 TRa1 appeared as a doublet band on most Western blots, suggesting that it may undergo posttranslational modifications in addition to palmitoylation. ERa undergoes methylation and phosphorylation, which regulate its association with other proteins, and in endothelial cells, membrane-bound ERa is part of a large, multiprotein "signalosome" that consists of G proteins (heterotrimeric guanine nucleotide-binding proteins), NOS3, Src, PI3K, Akt, and scaffolding proteins (33) . Thus, nongenomic signaling by ERa, TRa, and possibly other steroid receptor family members is evolutionarily conserved and uses similar mechanisms, converging on Src, ERK, and Akt to affect vital cellular functions.
Importance of nongenomic TH signaling in vivo
Serum TH concentrations are tightly controlled and stable, but tissue T3 concentrations may vary through regulated expression of iodothyronine deiodinases, TH transporters, and TH-binding proteins (2) . T3 reduces systemic vascular resistance and enhances cardiac contractility within 3 min, providing evidence for nongenomic TH signaling in vivo (37) . Regulation of vascular resistance is mediated, at least in part, by the TH-dependent stimulation of endothelial NOS3 (6), and NOS activity in various tissues correlates with the serum concentration of TH in rats (26) . Our finding of reduced serum cGMP concentrations in hypothyroid mice is consistent with the regulation of NOS activity by TH, although the source of cGMP in serum may include receptor GCs as well as sGCs. We found that the NO-independent sGC stimulator cinaciguat largely reversed the cGMP deficiency of hypothyroid mice, restoring osteoblastic bone formation and preventing osteocyte apoptosis. These results are in agreement with the NO-and cGMP-dependent effects of TH on osteoblasts and osteocytes observed in vitro, and suggest that nongenomic TH signaling controls bone formation and maintenance. Osteocyte survival is also regulated by nongenomic estrogen and androgen signaling, and enhanced osteocyte apoptosis contributes to poor bone quality in sex hormone-deficient animals (36) .
Clinical relevance of TH signaling in bone TH binding-deficient TRa1 mutations in humans cause growth retardation and skeletal dysplasia despite the presence of near-normal TH serum concentrations, supporting a role of TRa1 in skeletal development (2) . Both hypo-and hyperthyroidism are associated with excess fracture risk, which persists long after reestablishing normal TH serum concentrations (12) . Postmenopausal women are especially vulnerable to the skeletal effects of TH excess or deficiency because of the compounding effects of estrogen deficiency on bone. Cinaciguat mimicked the positive effects of TH on bone formation and osteocyte survival without having substantial effects on osteoclasts. These results suggest that agents that enhance cGMP abundance could serve as bone-anabolic agents in states of relative deficiency of NO or cGMP, such as hypothyroidism. By identifying a plasma membrane-localized TR coupled to the NO-cGMP-PKGII pathway, we have contributed to the understanding of nongenomic TH signaling. Because TH is crucial for skeletal development and maintenance, and because animal and clinical studies support the osteogenic functions of NO (38) , our results suggest a rationale for using cGMP-enhancing agents to treat osteoporosis.
MATERIALS AND METHODS
Reagents
THs, calcein, 2-bromo-palmitate, methyl-b-cyclodextrin, 2-hydroxymyristic acid, BrdU, deoxyribonuclease (DNase), and the BrdU-specific antibody were from Sigma. The PI3K inhibitor LY294002 was obtained from Calbiochem. The cGMP agonist 8-pCPT-cGMP and the cGMP antagonist Rp-CPT-PET-cGMPS were from Biolog. The NOS inhibitor L-NAME and the sGC inhibitor ODQ were obtained from Cayman. 
Plasmid and adenoviral constructs
Full-length rat complementary DNA (cDNA) sequences encoding TRa1 or TRb1 (a gift of H. Towle, Michigan State University) were cloned inframe with three C-terminal FLAG epitope tags into pcDNA3 (Life Technologies) (39) . N-terminal deletions of 351 or 375 nucleotides (from the first ATG) were generated by polymerase chain reaction (PCR), providing the natural Kozak sequences surrounding M120 and M122, or M150, respectively ( Fig. 2A) . The plasmid encoding NOS3-RFP was purchased from Addgene (no. 22497). Site-directed mutagenesis was performed with the QuikChange kit (Stratagene) according to the manufacturer's instructions. All PCR products were sequenced to ensure the absence of unwanted mutations. Adenoviral vectors encoding b-galactosidase (LacZ), FLAG-tagged or untagged versions of rat TRa or TRb (9) , and the untagged wild-type or G2A mutant PKGII (14) were generated with the pAd/CMV/V5-DEST Gateway system (Life Technologies). Typically, cells were infected 24 hours after transfection with siRNA in medium containing 0.1% FBS at a multiplicity of infection of~10. After 18 hours, fresh medium with 0.1% FBS was added.
Cell culture and treatments with hormones or drugs hPOBs were explant cultures established from trabecular bone fragments obtained from knee replacement operations according to an institutionally approved protocol (13, 14) . mPOBs were isolated from the calvariae of 5-to 7-day-old THRA f/f and THRB f/f mice and from the femurs and tibiae of 8-to 12-week-old NOS3 f/f mice, described below (14) . POBs were cultured in Dulbecco's modified Eagle's medium supplemented with 10% FBS. Cells were characterized as described in figs. S1A and S4C and were used at passages 1 to 5. MC3T3-E1 osteoblast-like cells (clone 4) were obtained from the American Type Culture Collection and were used at <12 passages and cultured in ascorbate-free, a-minimal essential medium (a-MEM) supplemented with 10% FBS (13) . Osteocyte-like MLO-Y4 cells were from L. F. Bonewald (University of Missouri-Kansas City) and were grown on collagen-coated plates in a-MEM supplemented with 2.5% enriched calf serum and 2.5% heat-inactivated FBS. Before drug treatment, the medium of subconfluent cell cultures was changed to phenol red-free medium containing 0.1 or 10% charcoal-stripped FBS (which is referred to as hormone-free medium) for 18 to 24 hours. Cells were preincubated with pharmacological inhibitors or vehicle for 30 min, as indicated in the legends. T3 and T4 were made as 10 mM stock solutions in 0.1 N NaOH, diluted in culture medium, and added without exposing cells to fluid shear stress. Control cultures received the same volume of medium.
Mouse experiments
In THRA f/f and THRB f/f mice, exons 2 and 7 were flanked by loxP sites, respectively, and excision leads to a frame shift. In NOS3 f/f mice, exons 2 to 9 (NOS3) were flanked by loxP sites. POBs were isolated as described earlier and infected with adenovirus encoding Cre recombinase, and the efficiency of Cre-mediated excision of the floxed alleles was determined by RT-PCR assay ( fig. S1D ) or Western blotting analysis (Fig. 4H) . Twelve-week-old male C57BL6/J mice were from The Jackson Laboratory and received normal mouse chow for 5 days. Half of the mice were then switched to the same chow formulation that was deficient in iodine and contained 0.05% PTU (Harlan Laboratories). After 4 days, mice were randomized to receive daily intraperitoneal injections of vehicle or cinaciguat (10 mg/kg per day) for 4 weeks. After 2 weeks, heart rates were measured with a tail cuff. At 7 and 4 days before euthanasia, all mice received calcein (25 mg/kg intraperitoneally). Mice were euthanized by CO 2 asphyxiation and exsanguination, and femurs and tibiae were removed and processed as described in a later section. All experiments were approved by the Institutional Animal Care and Use Committee of the University of California, San Diego.
Transfection of cells with DNA and siRNA
Cells were transfected when they had achieved 60 to 80% confluency (for DNA) or 30 to 40% confluency (for siRNA) using 5 µl of Lipofectamine 2000 and a total of 2 µg of DNA or 100 pmol of siRNA in 1 ml of normal serum-containing medium per six-well dish. Cells were then transferred to hormone-deficient medium after 6 hours. Experimental treatments occurred 48 hours after transfection, unless stated otherwise. The sequences targeted by these siRNAs are described in table S2. mRNA knockdown was quantified by real-time RT-PCR in parallel experiments. Protein depletion by the siRNAs targeting PKGI, PKGII, Src, or the b 3 integrin subunit was previously shown in MC3T3 cells (14) .
Cell fractionation, purification of p30 TRa1-FLAG, T3-agarose pull-downs, and Western blotting analysis Cells were extracted by Dounce homogenization in lysis buffer [0.25 M sucrose, 20 mM Tricine (pH 7.2), 1 mM EDTA with protease inhibitor cocktail (Calbiochem)], and nuclei and cell debris were removed by centrifugation at 1000g for 10 min. The supernatant was layered over a cushion of 30% Percoll (Sigma cat. no. D1644) in lysis buffer and centrifuged at 84,000g for 30 min. The plasma membrane layer was aspirated ("percoll membranes"), and in some experiments, membranes were further fractionated over a discontinuous gradient of 45%-35%-5% Optiprep (Sigma cat. no. P1556) after mixing the percoll membranes with 45% Optiprep and centrifuging the gradient at 52,000g for 2 hours (40). Twelve 1-ml fractions were collected from the top down, and proteins in each fraction were concentrated by chloroform-methanol precipitation. To purify FLAG-p30 TRa1, human embryonic kidney (HEK) 293T cells transfected with plasmid encoding FLAG-tagged TRa1-D149 were lysed in 1% Triton X-100, 0.1% sodium deoxycholate, 50 mM tris-HCl (pH 7.5), and protease inhibitor cocktail. After centrifugation at 16,000g for 30 min, cleared lysates were incubated with anti-FLAG antibody covalently bound to agarose beads for 15 min on ice. Beads were washed in lysis buffer with 250 mM NaCl, and bound proteins were eluted with FLAG peptide. Purity and protein concentrations were estimated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie staining, with bovine serum albumin (BSA) serving as a standard. T3-Sepharose and control resin were prepared in parallel with activated CH-Sepharose 4B (Sigma-Aldrich) according to a published procedure (41) . Briefly, T3 or vehicle (0.1 N NaOH) was added to the washed resin and mixed for 2 hours at room temperature. The suspension was washed three times for 5 min with a solution of 0.1 M tris-HCl (pH 8.0) and 0.5 M NaCl, and three times with 0.1 M sodium acetate and 0.5 M NaCl (pH 4). Cell membranes were solubilized with 1% Triton X-100 and 1% NP-40, and incubated for 30 min at 4°C with T3-Sepharose or control resin equilibrated with binding buffer containing 1% Triton X-100, 1% NP-40, 0.25 M sucrose, 20 mM tris-HCl (pH 7.8), 1 mM EDTA, and protease inhibitor cocktail. After six washes, bound proteins were eluted in SDS-sample buffer and analyzed by SDS-PAGE and Western blotting. Western blots were incubated with horseradish peroxidase-conjugated secondary antibodies, and protein bands were detected with an enhanced chemiluminescence system, as described previously (13) . Films in the linear range of exposure were scanned with ImageJ software [W. Rasband, National Institutes of Health (NIH)].
Quantitative RT-PCR assays RNA was isolated from cells or bone with TRIzol reagent (14) . Femurs, dissected free of soft tissue, with epiphyses cut off and bone marrow flushed out, were flash-frozen, stored, and pulverized at −80°C. One microgram of total RNA was reverse-transcribed, and quantitative PCR was performed with an MX3005P real-time PCR detection system with Brilliant II SYBR Green qPCR Master Mix (Agilent Technologies) (13) . Primer sequences are described in table S3. All primers produced a single product and linear amplification plots. Relative changes in mRNA abundance were determined with the 2 −DDCt method, with gapdh mRNA serving as an internal reference (13) . Absolute amounts of TRa and TRb mRNA were calculated from standard curves from PCR-amplified TRa and TRb cDNA fragments, respectively, at dilutions corresponding to 10 3 to 10 6 copies.
Preparation of bone cell membrane extracts
Protein extracts were prepared from the bones of control and hypothyroid mice as described previously (42) . Frozen bones were pulverized with a mortar and pestle in liquid nitrogen. The bone powder was incubated for 15 min on ice in the following lysis buffer: 50 mM tris-HCl (pH 8.0), 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, 2 mM NaVO 4 , 10 mM NaF, plus protease inhibitor cocktail. The samples were centrifuged at 13,000g for 15 min at 4°C, and 2 ml of supernatant (combined from two femurs and two tibiae per mouse) was concentrated by chloroform-methanol precipitation. The protein pellet was suspended in 100 µl of SDS sample buffer. Proteins were resolved on a 12.5% gel and were analyzed by Western blotting with an anti-TRa1 antibody.
Quantitation of NO x
NO production was measured on the basis of nitrite and nitrate accumulation in the medium with a two-step colorimetric assay, as previously described (13) .
Measurement of intracellular Ca 2+ concentrations
POBs were plated on glass coverslips and starved for 18 hours in phenol red-free a-MEM containing 0.1% charcoal-stripped FBS. Cells were labeled with 5 mM Fura-2/AM for 30 min at 37°C. In some experiments, cells were pretreated with 2 mM EGTA for 1 hour, and Fura-2 was added during the last 30 min. Cells were gently washed, and fresh hormone-free medium was added before the experiment. The coverslip was carefully lifted out of the culture dish with~100 ml of medium on top and placed into the inverted microscope chamber (Motic AE31). Cell ensembles were illuminated at wavelengths of 340 and 380 nm, and the emitted light was passed through a 510-nm interference filter and detected by a photomultiplier tube. Images were recorded with the IonOptix fluorescence system interface and analyzed with IonWizard 6.3 image analysis software. After recording baseline fluorescence for 3 min, TH, vehicle, or ATP was added to the medium containing 2× concentrations, taking great care to avoid fluid shear stress. Intracellular Ca 2+ values were calculated from the 340:380 nm ratio. Fura-2 calibration parameters were determined as previously described (43) . . Cell lysates were subjected to immunoprecipitation with anti-FLAG antibody, and immunoprecipitates were analyzed by SDS-PAGE. Gels were soaked in Fluoro-Hance (Research Products International) and exposed for autoradiography. One percent of eluates from immunoprecipitates were analyzed separately by Western blotting with an anti-FLAG antibody.
PLA and immunofluorescence staining
MC3T3 cells were plated on glass coverslips in 24-well plates and transfected with 150 ng of plasmid encoding FLAG-tagged TRa1-D149 or with 100 ng of plasmid encoding Myc-tagged TRa1-D149 together with plasmid encoding NOS3-RFP (NOS3 C-terminally fused to RFP). After 24 hours, cells were fixed with 3.7% paraformaldehyde, permeabilized in 0.5% Triton X-100, and blocked in phosphate-buffered saline, containing 3% BSA. For the PLA, cells transfected with plasmid encoding TRa1-D149-FLAG were incubated with murine anti-FLAG antibody (at a 1:1000 dilution) and rabbit anti-caveolin-1 antibody (1:100) together with FITCconjugated phalloidin (1:1000, Life Technologies). PLAs were performed with the Duolink In Situ kit (Olink Bioscience) according to the manufacturer's instructions. For immunofluorescence, cells were incubated with rabbit anti-FLAG, murine anti-caveolin-1, or murine anti-Myc antibodies, followed by FITC-or TRITC (tetramethyl rhodamine isothiocyanate)-labeled secondary antibodies, or both (Jackson ImmunoResearch). Nuclei were counterstained with Hoechst 33342. Cells were viewed with a confocal microscope (Olympus FV1000) with a 60/1.42 objective, using a 6× digital zoom. Images were analyzed with FluoView (Olympus) and Photoshop (Adobe) for sizing and contrast adjustment.
BrdU uptake assays
hPOBs were plated on glass coverslips, infected with LacZ-or Creexpressing virus for 24 hours, and transferred to hormone-deficient medium for 24 hours before the addition of 1 nM T3 for 30 min. BrdU (200 µM) in fresh hormone-deficient medium was then added for 18 hours. Similar results were obtained when T3 was present during the 18-hour BrdU labeling period. Cells were fixed, permeabilized, and incubated with DNase I before incubation with an anti-BrdU antibody and Hoechst 33342, as previously described (14) .
Measurement of cell death
POBs were infected with Cre-or LacZ-expressing viruses. Twenty-four hours later, cells were transferred to hormone-free medium containing 10% FBS for 24 hours, and some TRa-deficient cells were infected with adenovirus expressing TRa1 to reconstitute the protein. Cells were then incubated for 18 hours with fresh hormone-free medium containing 0.1% (starved) or 10% (control) charcoal-stripped FBS and were treated with T3 or vehicle as indicated in the figure legends. A minimum of 200 cells for each condition were examined for trypan blue uptake, and serum starvation-induced cell death was calculated by subtracting the percentage of trypan blue-positive cells in medium containing 10% FBS from the percentage of trypan blue-positive cells in medium containing 0.1% FBS. To detect apoptosis, caspase-3 cleavage was assessed by Western blotting. MLO-Y4 cells received the indicated pharmacological inhibitor or vehicle for 1 hour before being incubated with 1 nM T3 or vehicle for 1 hour. Cells were then treated for 8 hours with 50 mM etoposide, which induces apoptosis by forming a ternary complex with topoisomerase II and DNA, preventing DNA religation, and causing double-stranded DNA breaks. Etoposideinduced cell death was calculated by subtracting the percentage of trypan blue-positive cells in the untreated cultures from the percentage of trypan blue-positive cells in the etoposide-treated cultures.
Osteocyte apoptosis in vivo was quantified by TUNEL staining with the ApopTag Peroxidase In Situ Apoptosis Detection Kit (Millipore, cat. no. S7100) on nondecalcified sections. Sections were deplasticized by incubation in 2-methoxyethyl acetate (three times each for 20 min), acetone (twice each for 5 min), and deionized water (twice each for 5 min). Sections were then incubated in 10 mM citrate buffer (pH 7.6) at 98°C for 5 min, which was followed by incubation with 0.5% pepsin in 0.1 N HCl for 30 min at 37°C. The TUNEL reaction was performed according to the manufacturer's instructions, and slides were counterstained with 0.5% methyl green. A minimum of 200 osteocytes surrounded by bone matrix were counted in either the cortical or trabecular bone, and the percentage of TUNEL-positive apoptotic cells with black nuclei was calculated. Microscopic results were confirmed by an independent observer, who counted samples in a blinded fashion.
Bone histomorphometry
Right femurs were fixed in 70% ethanol, dehydrated in graded concentrations of ethanol and xylene, and embedded in methyl methacrylate (without decalcification) at the University of Alabama, Birmingham, Center for Metabolic Bone Disease. Unstained 8-mm-thick frontal sections were used for assessing dynamic bone turnover parameters from fluorochrome labeling, and trichrome-stained sections were used for static parameters. One mouse per experimental group had to be excluded from the analysis because of insufficient calcein absorption and inadequate labeling. Slides were scanned with a Hamamatsu NanoZoomer 2.0HT Slide Scanning System, and image analysis was performed with NanoZoomer Digital Pathology NDP.view2 software. All histomorphometric measurements were performed in trabecular bone between 1250 and 250 mm proximal to the growth plate and excluding the cortex, and in cortical bone between 5 and 0.25 mm proximal to the growth plate in distal femurs (as shown in Fig. 6C ). Total bone surface (BS), the percentage of single-and double-labeled bone surfaces (sLS and dLS), and interlabel width (average of six measurements per bone) were measured at the endocortical surfaces, as well as on trabecular surfaces in the secondary spongiosa. Mineralizing surface [MS/BS = (dLS + 1 / 2 sLS)/BS], mineral apposition rate [MAR = interlabel width/labeling time interval], and bone formation rate [BFR = MAR(MS/BS)] at endosteal and trabecular surfaces were calculated according to convention. A minimal MAR value of 0.3 mm/day was used in PTU-treated animals lacking double labeling (44) . Osteoblast and osteoclast numbers were expressed as two-dimensional parameters per millimeter of bone perimeter (B.Pm), as recommended by the ASBMR Histomorphometry Nomenclature Committee (44) . Histomorphometry results were confirmed by an independent, blinded observer. 
Data presentation and statistical analyses
Data in bar graphs are the means ± SEM of at least three independent experiments, and Western blots and autoradiographs represent three independent experiments, unless stated otherwise. GraphPad Prism 5 was used for two-tailed Student's t test (to compare two groups) or one-way analysis of variance (ANOVA) with Bonferroni posttest analysis (to compare more than two groups). P < 0.05 was considered statistically significant.
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